NCT04966676View on ClinicalTrials.gov

Study of Nivolumab-Ipilimumab and cfDNA in Lung Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

January 24, 2022

Primary Completion Date

November 1, 2025

Study Completion Date

November 1, 2025

Conditions
Non Small Cell Lung Cancer
Interventions
DIAGNOSTIC_TEST

cfDNA blood test

Blood sample will be taken for cfDNA testing

DRUG

Nivolumab

Antineoplastic agent

DRUG

Ipilimumab

Antineoplastic agent

COMBINATION_PRODUCT

Platinum-based Chemotherapy

May include carboplatin with gemcitabine, or paclitaxel or pemetrexed

Trial Locations (1)

M5G 2M9

Princess Margaret Cancer Centre, Toronto

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

University Health Network, Toronto

OTHER

NCT04966676 - Study of Nivolumab-Ipilimumab and cfDNA in Lung Cancer | Biotech Hunter | Biotech Hunter